急性呼吸窘迫综合征的药物治疗进展  

Update on Pharmacological treatments in acute respiratory distress syndrome

作　　者：杨艺[1] YANG Yi(Department o f Respiration Medicine , People's Hospital o f Baise ,Baise 533000 ,Guangxi, China)

机构地区：[1]广西壮族自治区百色市人民医院呼吸内科,广西百色533000

出　　处：《川北医学院学报》2016年第3期443-446,共4页Journal of North Sichuan Medical College

摘　　要：急性呼吸窘迫综合征(ARDS)是临床危重症,呼吸支持治疗是ARDS的基础治疗方案,在呼吸支持治疗的基础上给予合理用药,控制过度全身性炎症反应,促进促炎/抗炎平衡的恢复,对治疗ARDS至关重要。ARDS的治疗药物包括抗炎治疗(糖皮质激素、他汀类药)、抗氧化治疗(N-乙酰半胱氨酸、维生素类及氨溴索)、外源性肺泡表面活性物质(PS)替代疗法、血管活性药物(一氧化氮和前列腺素E1)、重组人活性蛋白C、干细胞治疗等。综合考虑多种病理机制,联合多种药物,或药物与非药物干预联合应用是目前较为公认的ARDS治疗方向。Respiration supporting is considered as a basic treatment for acute respiratory distress syndrome ( ADRS) , and additionalpharmacological treatments play an important role in control of systemic inflammatory response and balance proinflammatory /a n ti-inflammatory. Pharmacological treatments for ARDS include anti - inflammation thearpy (glucocorticoid and statins) ,antioxidant therapy(n - acetylcysteine, vitamins and ambroxol) , endogenous pulmonary surfactant (PS) replacement therapy, vasoactive agents therapy(nitric oxide and prostaglandin E l) , recombinant human activated protein C and stem cell treatment. Given the variety of pathologicalmechanism, the multi-drug regimens, drug combined non - drug treatment are recognized as direction of treatment for ARDS.

关 键 词：急性呼吸窘迫综合征 糖皮质激素 内源性肺泡表面活性物质 肺损伤 

分 类 号：R563.8[医药卫生—呼吸系统]